Renal Tumor (Localized) · Surveillance/Ablation/Partial vs Radical

Step-by-step decision

Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.

🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).

Full pathway

1. [Decision] Size/stage + renal function/comorbidity
   Tumor size/stage? Renal function/life expectancy?
   • cT1a (≤4 cm), operable → cT1a · choose modality
   • cT1b–T2 (>4 cm, localized) → cT1b–T2 · partial vs radical
   • Elderly/short life expectancy/high surgical risk (especially <2 cm) → Active surveillance
   • cT3+/venous tumor thrombus/locally advanced → cT3+ → radical nephrectomy
2. [Decision] cT1a · choose modality
   Partial nephrectomy / ablation / surveillance?
   • Partial nephrectomy preferred (nephron-sparing) → Partial nephrectomy (nephron-sparing)
   • ≤3 cm + high surgical risk/comorbidity → thermal ablation → Thermal ablation
   • <2 cm/elderly/comorbidity → active surveillance → Active surveillance
3. [End] Partial nephrectomy (nephron-sparing)
   Partial nephrectomy — preferred for cT1a (complete tumor excision + maximal renal function preservation); laparoscopic/robotic or open.
4. [End] Thermal ablation
   Thermal ablation (radiofrequency/cryoablation) — ≤3 cm, high surgical risk/comorbidity; good renal function preservation; needs core biopsy for pathology + imaging follow-up.
5. [End] Active surveillance
   Active surveillance — small tumor (especially <2 cm), elderly/comorbidity/short life expectancy; serial imaging, intervene on progression (growth/upstaging).
6. [End] cT1b–T2 · partial vs radical
   cT1b–T2 localized → partial nephrectomy preferred when feasible to preserve nephrons, otherwise radical nephrectomy; complex/unfavorable location → radical.
7. [End] cT3+ → radical nephrectomy
   cT3+/venous tumor thrombus/locally advanced → radical nephrectomy (± thrombectomy/lymphadenectomy); metastatic disease gets systemic therapy (immunotherapy ± targeted) + cytoreduction assessment.

Source guidelines & references

• Renal mass and localized renal cancer management (AUA guideline Part I/II 2021)

This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.

Other pathways